Just launched · October 2026—Rankings get sharper with every edition.Spotted an error?Tell us →
Sign in / Register

MICIN

Active#44 in Japan

Estimated valuation · Telemedicine and clinical trials · Japan

Provides online medical consultation, decentralised clinical-trial tools and digital insurance products that connect patients, hospitals and pharmaceutical companies in Japan.

Founded2015
HQTokyo
Last roundSeries C · Oct 2023
Country of originJapanListed in the Japan ranking
Where would you invest?JapanJurisdiction as cited by the ranking

Estimated valuation

AI · Japan ranking
≈ USD 100MUSD 81–130M · Hundreds of M$
Published valuation
USD 101.5M · May 2026
AI adjustment
None

An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method

Uback rankings

How the AI ranks →
RankingTierRankEditionNext update
Japan · all sectorsTop 50#44Edition 0 · October 202610 Jan 2027
Rank historyOct 2026 · #44First edition: no movements yet.

Funding history

DateRoundAmountTypeInvestors
Oct 2023Series Camount undisclosed——

Post-money about JPY 16.0bn (estimate incl. potential shares).

Rounds as cited by Uback’s rankings. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of MICIN as a PDF. It must answer at least one of these four questions, and stick to them:

AI valuation: $100MUndervalued or overvalued?
Versus competitorsHow does it compare?
Who should acquire itStrategic buyers, and why
Who should it acquireAcquisition targets, and why
Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication.

Comparable companies in Japan

Full Japan ranking →

Last updated: Oct 2026Report an error

Uback is a content publisher and an aggregator of non-binding expressions of interest. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.